In a report published Friday, BTIG Research analyst Dane Leone initiated coverage on Illumina, Inc. ILMN with a Buy rating and $220.00 price target.
In the report, BTIG Research noted, “We think ILMN is a good investment for long‐term investors as opportunities in the clinical diagnostics space along with a highly flexible balance sheet allow the company to develop from a ‘product' company, currently dependent on NGS technology cycles, to a ‘portfolio' company managing an array of product lines that extend from its core leadership position in NGS. We rate ILMN Buy with a target price of US$220. While there is risk for a pullback in the stock near term, we like the long term story, and would advise longer term investors to buy the dips.”
Illumina, Inc. closed on Thursday at $159.54.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in